Global dementia and alzheimer’s disease treatment market is expected to grow at a CAGR of close to 10% during the forecast period. The global dementia and alzheimer’s disease treatment market is driven by rising social awareness regarding the diseases. Moreover, growing old age population, which is usually more prone to such diseases, is positively impacting the growth of market. Also, upsurge in R&D activities associated with disease modifying drugs, is further expected to bolster the growth of market over the next few years.

The global dementia and alzheimer’s disease treatment market is segmented based on drug class, distribution channel, company and region. Based on drug class, the market can be categorized into cholinergic/cholinesterase (ChE) inhibitors, memantine, and combination drugs. Out of these, the cholinergic/cholinesterase (ChE) inhibitor segment dominates the dementia and Alzheimer’s disease market, in terms of value, which can be accredited to fact that it is first line of treatment for AD and most widely prescribed drug for the treatment of AD. In addition to this, due to its effectiveness for treating mild to severe dementia, which is contributing to the increasing growth of the segment. Also, the memantine segment is further expected to be the fastest growing segment during the forecast period which can be attributed to its suitability in cholinergic/cholinesterase inhibitors intolerant patients suffering from AD.

Major players operating in the global dementia and alzheimer’s disease treatment market include Merz Pharma GmbH & Co. KGaA, Novartis AG, Allergan plc., Pfizer, Inc., Daiichi Sankyo Company, Limited, Ono Pharmaceutical Co., Ltd., Johnson & Johnson Services, Inc., Eisai Co., Ltd., H. Lundbeck A/S, F. Hoffmann-La Roche Ltd., AbbVie Inc., Eli Lilly and Company, Biogen, INmuneBIO, AstraZeneca and others. The companies are adopting new strategies in order to stay competitive in the market. Rising competitiveness is anticipated to drive innovation in the market, thereby helping the industry to solve existing challenges and meet the needs of the market.

Objective of the Study:

  • To analyze and estimate the market size of global dementia and alzheimer’s disease treatment market from 2017 to 2020.
  • To estimate and forecast the market size of global dementia and alzheimer’s disease treatment market from 2021 to 2027 and growth rate until 2027.
  • To classify and forecast global dementia and alzheimer’s disease treatment market based on drug class, distribution channel, company and regional distribution.
  • To identify dominant region or segment in the global dementia and alzheimer’s disease treatment market.
  • To identify drivers and challenges for global dementia and alzheimer’s disease treatment market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global dementia and alzheimer’s disease treatment market.
  • To conduct pricing analysis for global dementia and alzheimer’s disease treatment market.
  • To identify and analyze the profile of leading players operating in global dementia and alzheimer’s disease treatment market.
  • to identify key sustainable strategies adopted by market players in global dementia and alzheimer’s disease treatment market.


Click here to download the sample

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of companies across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufacturers which could not be identified due to the limitations of secondary research. TechSci Research analyzed the hospitals and presence of all major players across the globe.

TechSci Research calculated the market size of global dementia and alzheimer’s disease treatment market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:

  • Dementia and alzheimer’s disease treatment facilities and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, forums and alliances related to dementia and alzheimer’s disease treatment
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as companies, partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Attribute

Details

Base Year

2021

Historical Data

2017 – 2020

Estimated Year

2022

Forecast Period

2023 – 2027

Quantitative Units

Revenue in USD Million and CAGR for 2017-2021 and 2022E-2027F

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments covered

  • Type
  • Distribution Channel

Regional scope

North America; Europe; Asia Pacific; South America; Middle East & Africa

Country scope

United States, Mexico, Canada, China, India, Japan, South Korea, Australia; Germany, France, United Kingdom, Spain, Italy; South Africa, UAE, Saudi Arabia; Brazil, Argentina, Colombia;

Key companies profiled

Merz Pharma GmbH & Co. KGaA, Novartis AG, Allergan plc., Pfizer, Inc., Daiichi Sankyo Company, Limited, Ono Pharmaceutical Co., Ltd., Johnson & Johnson Services, Inc., Eisai Co., Ltd., H. Lundbeck A/S, F. Hoffmann-La Roche Ltd., AbbVie Inc., Eli Lilly and Company, Biogen, INmuneBIO, AstraZeneca.

Customization scope

10% free report customization with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Delivery Format

PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

 

Report Scope:

In this report, global dementia and alzheimer’s disease treatment market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Global Dementia and Alzheimer’s Disease Treatment Market, By Drug Class:
    • Cholinergic/ Cholinesterase Inhibitors
      • Donepezil
      • Galantamine
      • Rivastigmine
    • Memantine
    • Combination Drugs
      • Memantine
      • Donepezil
  • Global Dementia and Alzheimer’s Disease Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Dementia and Alzheimer’s Disease Treatment Market, By Region:
    • North America
      • United States
      • Canada
      • Mexico
    • Europe
      • Germany
      • France
      • United Kingdom
      • Italy
      • Spain
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
    • Middle East & Africa
      • South Africa
      • Saudi Arabia
      • UAE
    • South America
      • Brazil
      • Argentina
      • Colombia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global dementia and alzheimer’s disease treatment market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Global dementia and alzheimer’s disease treatment market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com

In case you don’t find what you are looking for, please get in touch with our custom research team at sales@techsciresearch.com

1.    Product Overview

2.    Research Methodology

3.    Impact of COVID-19 on Global Dementia and Alzheimer’s Disease Treatment Market

4.    Executive Summary

5.    Voice of Customer

6.    Global Dementia and Alzheimer’s Disease Treatment Market Outlook

6.1.  Market Size & Forecast

6.1.1.     By Value

6.2.  Market Share & Forecast

6.2.1.     By Drug Class (Cholinergic/ Cholinesterase (ChE) Inhibitors [Donepezil, Galantamine, Rivastigmine], Memantine, Combination Drugs [Memantine & Donepezil]

6.2.2.     By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies)

6.2.3.     By Company (2021)

6.2.4.     By Region

6.3.  Market Attractiveness Index

7.    Asia-Pacific Dementia and Alzheimer’s Disease Treatment Market Outlook

7.1.  Market Size & Forecast          

7.1.1.     By Value

7.2.  Market Share & Forecast

7.2.1.     By Drug Class

7.2.2.     By Distribution Channel

7.2.3.     By Country

7.3.  Asia-Pacific: Country Analysis

7.3.1.     China Dementia and Alzheimer’s Disease Treatment Market Outlook

7.3.1.1.         Market Size & Forecast

7.3.1.1.1.             By Value

7.3.1.2.         Market Share & Forecast

7.3.1.2.1.             By Drug Class

7.3.1.2.2.             By Distribution Channel

7.3.2.     India Dementia and Alzheimer’s Disease Treatment Market Outlook

7.3.2.1.         Market Size & Forecast

7.3.2.1.1.             By Value

7.3.2.2.         Market Share & Forecast

7.3.2.2.1.             By Drug Class

7.3.2.2.2.             By Distribution Channel

7.3.3.     Australia Dementia and Alzheimer’s Disease Treatment Market Outlook

7.3.3.1.         Market Size & Forecast

7.3.3.1.1.             By Value

7.3.3.2.         Market Share & Forecast

7.3.3.2.1.             By Drug Class

7.3.3.2.2.             By Distribution Channel

7.3.4.     Japan Dementia and Alzheimer’s Disease Treatment Market Outlook

7.3.4.1.         Market Size & Forecast

7.3.4.1.1.             By Value

7.3.4.2.         Market Share & Forecast

7.3.4.2.1.             By Drug Class

7.3.4.2.2.             By Distribution Channel

7.3.5.     South Korea Dementia and Alzheimer’s Disease Treatment Market Outlook

7.3.5.1.         Market Size & Forecast

7.3.5.1.1.             By Value

7.3.5.2.         Market Share & Forecast

7.3.5.2.1.             By Drug Class

7.3.5.2.2.             By Distribution Channel

8.    Europe Dementia and Alzheimer’s Disease Treatment Market Outlook

8.1.  Market Size & Forecast          

8.1.1.     By Value

8.2.  Market Share & Forecast

8.2.1.     By Drug Class

8.2.2.     By Distribution Channel

8.2.3.     By Country

8.3.  Europe: Country Analysis

8.3.1.     France Dementia and Alzheimer’s Disease Treatment Market Outlook

8.3.1.1.         Market Size & Forecast

8.3.1.1.1.             By Value

8.3.1.2.         Market Share & Forecast

8.3.1.2.1.             By Drug Class

8.3.1.2.2.             By Distribution Channel

8.3.2.     Germany Dementia and Alzheimer’s Disease Treatment Market Outlook

8.3.2.1.         Market Size & Forecast

8.3.2.1.1.             By Value

8.3.2.2.         Market Share & Forecast

8.3.2.2.1.             By Drug Class

8.3.2.2.2.             By Distribution Channel

8.3.3.     United Kingdom Dementia and Alzheimer’s Disease Treatment Market Outlook

8.3.3.1.         Market Size & Forecast

8.3.3.1.1.             By Value

8.3.3.2.         Market Share & Forecast

8.3.3.2.1.             By Drug Class

8.3.3.2.2.             By Distribution Channel

8.3.4.     Italy Dementia and Alzheimer’s Disease Treatment Market Outlook

8.3.4.1.         Market Size & Forecast

8.3.4.1.1.             By Value

8.3.4.2.         Market Share & Forecast

8.3.4.2.1.             By Drug Class

8.3.4.2.2.             By Distribution Channel

8.3.5.     Spain Dementia and Alzheimer’s Disease Treatment Market Outlook

8.3.5.1.         Market Size & Forecast

8.3.5.1.1.             By Value

8.3.5.2.         Market Share & Forecast

8.3.5.2.1.             By Drug Class

8.3.5.2.2.             By Distribution Channel

9.    North America Dementia and Alzheimer’s Disease Treatment Market Outlook

9.1.  Market Size & Forecast          

9.1.1.     By Value

9.2.  Market Share & Forecast

9.2.1.     By Drug Class

9.2.2.     By Distribution Channel

9.2.3.     By Country

9.3.  North America: Country Analysis

9.3.1.     United States Dementia and Alzheimer’s Disease Treatment Market Outlook

9.3.1.1.         Market Size & Forecast

9.3.1.1.1.             By Value

9.3.1.2.         Market Share & Forecast

9.3.1.2.1.             By Drug Class

9.3.1.2.2.             By Distribution Channel

9.3.2.     Mexico Dementia and Alzheimer’s Disease Treatment Market Outlook

9.3.2.1.         Market Size & Forecast

9.3.2.1.1.             By Value

9.3.2.2.         Market Share & Forecast

9.3.2.2.1.             By Drug Class

9.3.2.2.2.             By Distribution Channel

9.3.3.     Canada Dementia and Alzheimer’s Disease Treatment Market Outlook

9.3.3.1.         Market Size & Forecast

9.3.3.1.1.             By Value

9.3.3.2.         Market Share & Forecast

9.3.3.2.1.             By Drug Class

9.3.3.2.2.             By Distribution Channel

10.  South America Dementia and Alzheimer’s Disease Treatment Market Outlook

10.1.              Market Size & Forecast

10.1.1.  By Value

10.2.              Market Share & Forecast

10.2.1.  By Drug Class

10.2.2.  By Distribution Channel

10.2.3.  By Country

10.3.              South America: Country Analysis

10.3.1.  Brazil Dementia and Alzheimer’s Disease Treatment Market Outlook

10.3.1.1.      Market Size & Forecast

10.3.1.1.1.           By Value

10.3.1.2.      Market Share & Forecast

10.3.1.2.1.           By Drug Class

10.3.1.2.2.           By Distribution Channel

10.3.2.  Argentina Dementia and Alzheimer’s Disease Treatment Market Outlook

10.3.2.1.      Market Size & Forecast

10.3.2.1.1.           By Value

10.3.2.2.      Market Share & Forecast

10.3.2.2.1.           By Drug Class

10.3.2.2.2.           By Distribution Channel

10.3.3.  Colombia Dementia and Alzheimer’s Disease Treatment Market Outlook

10.3.3.1.      Market Size & Forecast

10.3.3.1.1.           By Value

10.3.3.2.      Market Share & Forecast

10.3.3.2.1.           By Drug Class

10.3.3.2.2.           By Distribution Channel

11.  Middle East and Africa Dementia and Alzheimer’s Disease Treatment Market Outlook

11.1.              Market Size & Forecast

11.1.1.  By Value

11.2.              Market Share & Forecast

11.2.1.  By Drug Class

11.2.2.  By Distribution Channel

11.2.3.  By Country

11.3.              MEA: Country Analysis

11.3.1.  South Africa Dementia and Alzheimer’s Disease Treatment Market Outlook

11.3.1.1.      Market Size & Forecast

11.3.1.1.1.           By Value

11.3.1.2.      Market Share & Forecast

11.3.1.2.1.           By Drug Class

11.3.1.2.2.           By Distribution Channel

11.3.2.  Saudi Arabia Dementia and Alzheimer’s Disease Treatment Market Outlook

11.3.2.1.      Market Size & Forecast

11.3.2.1.1.           By Value

11.3.2.2.      Market Share & Forecast

11.3.2.2.1.           By Drug Class

11.3.2.2.2.           By Distribution Channel

11.3.3.  UAE Dementia and Alzheimer’s Disease Treatment Market Outlook

11.3.3.1.      Market Size & Forecast

11.3.3.1.1.           By Value

11.3.3.2.      Market Share & Forecast

11.3.3.2.1.           By Drug Class

11.3.3.2.2.           By Distribution Channel

12.  Market Dynamics

12.1.              Drivers

12.2.              Challenges

13.  Market Trends & Developments

14.  Competitive Landscape

14.1.              Merz Pharma GmbH & Co. KGaA

14.2.              Novartis AG 

14.3.              Allergan plc.

14.4.              Pfizer, Inc.

14.5.              Daiichi Sankyo Company, Limited 

14.6.              Ono Pharmaceutical Co., Ltd.

14.7.              Johnson & Johnson Services, Inc.

14.8.              Eisai Co., Ltd.

14.9.              H. Lundbeck A/S

14.10.            F. Hoffmann-La Roche Ltd.

14.11.            AbbVie Inc.

14.12.            Eli Lilly and Company

14.13.            Biogen

14.14.            INmuneBIO

14.15.            AstraZeneca

15.  Strategic Recommendations

In case you don’t find what you are looking for, please get in touch with our custom research team at sales@techsciresearch.com